GlassScriptPhysician profile
Bryan Benjamin Grissett
NPI 1346747276
$8,276.06
in general payments reported to CMS, 2019-2025
28 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $533 · 2022: $726 · 2023: $1,227 · 2024: $4,225 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,876 · Travel and Lodging: $1,117 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,875.89 |
| Travel and Lodging | $1,117.10 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,797.02 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Novo Nordisk INC | $866.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $751.31 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $571.06 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $544.74 | 2021-2025 | Tepezza, Evenity, Prolia |
| Tandem Diabetes Care, INC. | $478.24 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $373.80 | 2023-2024 | Ilet Bionic Pancreas |
| Bayer Healthcare Pharmaceuticals INC. | $368.29 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $328.49 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $297.48 | 2023-2024 | |
| Corcept Therapeutics | $274.84 | 2024-2025 | Korlym |
| Esperion Therapeutics, INC. | $263.71 | 2021-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.11 | 2023-2025 | Jardiance, Synjardy, Trijardy Xr |
| Abbvie INC. | $199.21 | 2023-2025 | |
| Sequel Med Tech, LLC | $158.06 | 2024-2025 | Twiist |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $131.35 | 2023-2025 | Licart, Tirosint, Tirosint |
| Ascendis Pharma Endocrinology INC | $120.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $108.53 | 2022 | |
| Insulet Corporation | $97.42 | 2023-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $69.89 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $55.70 | 2023-2024 | Signifor Lar, Isturisa |
| Boston Scientific Corporation | $44.98 | 2024 | Wavewriter Alpha Prime 16 |
| Chiesi USA, INC. | $44.70 | 2024 | Mycapssa, Myalept |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Ascensia Diabetes Care US INC. | $21.96 | 2023 | |
| Pfizer INC. | $19.71 | 2024 | |
| Kyowa Kirin, INC. | $16.13 | 2024 | Crysvita |
| Madrigal Pharmaceuticals | $14.19 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Grissett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.